The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - HMP; MJH Life Sciences; Regeneron
Acute hospitalizations after proton beam therapy (PBT) versus intensity-modulated radiotherapy (IMRT) for locally advanced non–small-cell lung cancer (LA-NSCLC) in the era of immune checkpoint inhibitor (ICI) consolidation: A retrospective propensity score weighted study.
 
Michelle Iocolano
No Relationships to Disclose
 
Nikhil Yegya-Raman
No Relationships to Disclose
 
Xingmei Wang
No Relationships to Disclose
 
Cole Friedes
No Relationships to Disclose
 
Sang Ho Lee
No Relationships to Disclose
 
Lian Duan
No Relationships to Disclose
 
Bolin Li
No Relationships to Disclose
 
William P. Levin
Consulting or Advisory Role - Rocket VR Health
 
Keith A. Cengel
Stock and Other Ownership Interests - Symphotek; Symphotek
Consulting or Advisory Role - Novocure
Patents, Royalties, Other Intellectual Property - US20190099491A1 Sensitizing Cells to Proton Radiation; US9999779B2 Cell, tissue and organ protection using a magnetic field
Travel, Accommodations, Expenses - Novocure
 
Corey J. Langer
Honoraria - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly O.; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly O.; OncoCyte; Peregrine Pharmaceuticals; Synta
 
Roger B. Cohen
Honoraria - AstraZeneca
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Cantargia AB; Coherus Biosciences; Fstar Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Macrogenics (Inst); Xencor (Inst)
 
Lova Sun
No Relationships to Disclose
 
Charu Aggarwal
Consulting or Advisory Role - AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech; Janssen; Lilly; Merck; Pfizer; Sanofi/Regeneron; Shionogi; Turning Point Therapeutics
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Abigail Doucette
No Relationships to Disclose
 
Ying Xiao
No Relationships to Disclose
 
Kevin Teo
No Relationships to Disclose
 
Shannon O'Reilly
No Relationships to Disclose
 
Jennifer Wei Zou
Leadership - Protom
Stock and Other Ownership Interests - Kanington Management (I)
Consulting or Advisory Role - Starmap Medicine and Technology
 
Charles B. Simone
Honoraria - Novocure; Varian Medical Systems
 
Steven J Feigenberg
No Relationships to Disclose